Alnylam Corp (ALNY) Enterprise Value to EBITDA Ratio

Public company logo of alnylam.com (ALNY)

Alnylam Pharmaceuticals (ALNY) seeks to solidify its global leadership in RNA interference by pivoting from rare pathologies to mass-market diseases. This EV/EBITDA chart illustrates the valuation trend, where 20.90 represents the current metric level. Expectations for the drug Amvuttra support the increase in value, while operational flexibility is maintained through the engagement of external contract research and manufacturing organizations.

Alnylam Pharmaceuticals, Inc. - ALNY Company Value to EBITDA (period 11/23/2025 - 11/15/2026)

Comprehensive metric breakdowns and analytics for Alnylam Pharmaceuticals, Inc. (ALNY)

- current price and projected stock value:
Stock Price alnylam.com|ALNY - Analyst Median Target
- market capitalization details:
Market Valuation Alnylam|ALNY - Full Business Value
- business book valuation details:
Book Value per Share Alnylam|ALNY - Total Stockholders' Equity|Market Capitalization to Book Value Ratio alnylam.com|ALNY - Total Business Assets
- debt burden and liquidity indicators:
Total Debt to Equity Ratio Alnylam Pharmaceuticals|ALNY - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Alnylam|ALNY - Company Aggregate Indebtedness|Debts to Book Capitalization Alnylam Pharmaceuticals, Inc.|ALNY - Company Long-Term Loans and Borrowings|Company Short-Term Debts Alnylam|Quick Liquidity alnylam.com
- financial results and valuation multiples details:
ALNY - Final Profit|Expected Profit Alnylam Pharmaceuticals|ALNY - Price to Earnings Ratio|Forward P/E Multiple alnylam.com|ALNY - PEG Multiple|EV/EBITDA Multiple Alnylam|ALNY - Operating profit EBITDA|Earnings per share for the last twelve months Alnylam|ALNY - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last twelve months alnylam.com|ALNY - Earnings per share growth this year|Expected earnings per share growth for next year Alnylam Pharmaceuticals
- revenue and sales details:
ALNY - Company Total Revenue|Company Projected Revenue Alnylam Pharmaceuticals|ALNY - Price-to-Revenue Ratio|Forward P/S Multiple Alnylam|ALNY - Sales Growth YoY (TTM)
Fundamental valuation:Alnylam Pharmaceuticals ALNY
Manufactured products of Alnylam

Alnylam Pharmaceuticals (ALNY) develops high-cost RNAi drugs featuring colossal margins and low production costs. The EV/EBITDA multiple compares the total enterprise value with operating profit before depreciation, amortization, and interest. This metric allows investors to assess the real value of assets, stripped of debt burdens and tax distortions. By analyzing the current EV/EBITDA trend for Alnylam Pharmaceuticals (ALNY), one can timely recognize the risk of declining revenues hidden behind the superficial appeal of undervaluation.

Key competitors

EV/EBITDA Multiple VRTX (vrtx.com)|Total Company Value to Operating Income Before Depreciation Ratio Insmed (INSM)|UTHR: Enterprise Value to EBITDA Ratio|Company Value to Operating Income Before Depreciation Ratio BMRN|BBIO: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation BGM|COGT (Cogent Biosciences, Inc.) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation XERS (Xeris Biopharma Holdings)|Enterprise Value to EBITDA Ratio KROS (Keros Therapeutics, Inc.)|ARCT (Arcturus Therapeutics Inc) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Eton Pharmaceuticals, Inc. ETON|KMDA (Kamada Corp) - Company Value to Operating Income Before Depreciation Ratio|Fulcrum Therapeutics - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation ABEO (abeonatherapeutics.com)|MREO: EV/EBITDA Multiple|Protalix BioTherapeutics Inc. - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization pliantrx.com|APLT: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization aileronrx.com (RNTX)|Enterprise Value to EBITDA Ratio Gelteq GELS|EV/EBITDA Multiple AYTU (Aytu BioPharma Inc)|EV/EBITDA Multiple Chemomab CMMB|SRXH - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio PLRZ|AEZS: EV/EBITDA Multiple|Company Value to EBITDA Cyclo Therapeutics (CYTH)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Inozyme Pharma Inc.|Enterprise Value to Operating Income Before Depreciation RPHM (Reneo Pharmaceuticals, Inc.)|EV/EBITDA Multiple CSCI